About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.
CV Therapeutics Conference Call
Company management will webcast a conference call on Friday, April 11,
2008 at 8:30 a.m. EDT, 5:30 a.m. PDT, on the company's website. To access
the live webcast and corresponding slides, please log on to the Company's
website at http://www.cvt.com and go to the Investor Information section.
Alternatively, domestic callers may participate in the conference call by
dialing (866) 524-6241, and international callers may participate in the
conference call by dialing (706) 679-3061. Webcast and telephone replays of
the conference call will be available approximately two hours after the
completion of the call through Friday, April 18, 2008. Domestic callers can
access the replay by dialing (800) 642-1
|SOURCE Astellas Pharma US, Inc.|
Copyright©2008 PR Newswire.
All rights reserved